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To increase the removal of middle-sized uremic toxins a new membrane with enhanced per-
meability and selectivity, called Medium Cut-Off membrane (MCO-Ci) has been developed
that at the same time ensures the retention of albumin. Because many middle-sized sub-
stances may contribute to micro-inflammation we hypothesized that the use of MCO-Ci
influences the inflammatory state in hemodialysis patients.
Methods
The randomized crossover trial in 48 patients compared MCO-Ci dialysis to High-flux dialy-
sis of 4 weeks duration each plus 8 weeks extension phase. Primary endpoint was the gene
expression of TNF-α and IL-6 in peripheral blood mononuclear cells (PBMCs), secondary
endpoints were plasma levels of specified inflammatory mediators and cytokines.
Results
After four weeks of MCO-Ci the expression of TNF-αmRNA (Relative quantification (RQ)
from 0.92 ± 0.34 to 0.75 ± 0.31, -18.5%, p<0.001)-α and IL-6 mRNA (RQ from 0.78 ± 0.80 to
0.60 ± 0.43, -23.1%, p<0.01) was reduced to a significantly greater extent than with High-
flux dialyzers (TNF mRNA-RQ: -14.3%; IL-6 mRNA-RQ: -3.5%). After retransformation of
logarithmically transformed data, measurements after MCO were reduced to 82% of those
after HF (95% CI 74%–91%). 4 weeks use of MCO-Ci resulted in long-lasting change in
plasma levels of several cytokines and other substances with a significant decrease for
sTNFR1, kappa and lambda free light chains, urea and an increase for Lp-PLA2 (PLA2G7)
compared to High-flux. Albumin levels dropped significantly after 4 weeks of MCO dialysis
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but increased after additional 8 weeks of MCO dialysis. Twelve weeks treatment with MCO-
Ci was well tolerated regarding the number of (S)AEs. In the extension period levels of CRP,
TNF-α-mRNA and IL-6 mRNA remained stable in High-flux as well as in MCO-Ci.
Conclusions
MCO-Ci dialyzers modulate inflammation in chronic HD patients to a greater extent com-
pared to High-flux dialyzers. Transcription of pro-inflammatory cytokines in peripheral leuko-
cytes is markedly reduced and removal of soluble mediators is enhanced with MCO dialysis.
Serum albumin concentrations stabilize after an initial drop. These results encourage further
trials with longer treatment periods and clinical endpoints.
Introduction
The uremic syndrome is characterized by retention of a large number of solutes that are nor-
mally eliminated by the kidney [1, 2]. Many of these uremic toxins are not cleared by standard
extracorporeal treatments, either because they are protein-bound or because their molecular
weight exceeds the pore size of the membrane used. The latter group is often called middle
molecules, consisting of compounds between 15 and 45 kDa such as β-2-microglobulin,
tumor-necrosis factor alpha (TNF-α), interleukins, complement factor D and others, many of
which are pro-inflammatory [1]. Although adverse effects or even toxicity has not been proven
for all of these substances, many of them are factors or at least indicators of unfavorable out-
come. For instance, an independent association between β-2-microglobulin levels and cardio-
vascular events was confirmed for different stages of chronic kidney disease (CKD) [3].
The incidence of cardiovascular disease in patients with CKD is very high and associated
with the retention of uremic solutes [1]. Efficient renal replacement therapies that remove ure-
mic toxins might reduce the high morbidity and mortality in end-stage renal disease (ESRD)
patients. Proving a clinical advantage of more efficient dialysis techniques has been difficult. A
benefit of High-flux dialysis compared to Low-flux dialysis with regards to all-cause mortality
could not be clearly shown in the HEMO trial [4], and the MPO study demonstrated a survival
advantage of High-flux only in subgroups (patients with low albumin and in diabetics) [5].
Hemodiafiltration (HDF) in post-dilution mode provides even more efficient removal of ure-
mic retention solutes compared to High-flux [6]; however, the debate on improvements of
clinical endpoints by HDF is still ongoing: three recent prospective randomized studies gave
conflicting results regarding the benefit of HDF on mortality [7],[8, 9]. All three studies
reported nevertheless a dose-response relationship with the largest benefit in the subgroups
with the highest substitution rates indicating that more efficient removal of uremic toxins
might be beneficial.
To increase clearance of middle-sized molecules, highly permeable high cut-off dialyzers
have been developed [10]. In a previous clinical trial we showed that treatment reduced multiple
immune mediators in plasma (e.g. sTNFR1 by the use of these membranes [11]) and influences
in vitro vascular calcification.[12] However, the routine treatment of chronic dialysis patients
with HCO membranes is limited by significant losses of albumin [13]. Recently, a new mem-
brane type with a steeper and lower cut-off, called medium cut-off membrane (MCO-Ci) has
been developed [14]. The tailored pore sizes of these MCO-Ci membranes promote removal of
large toxins while ensuring the retention of albumin. In a preceding clinical trial, the character-
istics of MCO membranes were examined in single-session and it has been shown that these
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dialyzers provide improved clearance for middle molecules compared to High-Flux dialysis and
High-Flux-Hemodiafiltration. [15]
Here, we report the results of a clinical trial using the MCO-Ci dialyzer for up to 12 weeks
in a randomized, prospective, cross-over design in 50 chronic dialysis patients. This trial was




This trial was a randomized, open-label, cross-over study. 50 chronic hemodialysis patients
were randomized at two outpatient dialysis centers. (KfH dialysis centers at University of
Halle/Saale and Charite´ Campus Virchow University Hospital Berlin, Germany) The first
patient was included February 10th 2014, the study was finished July 29th 2014. The intention
to treat population consisted of 48 patients while 47 completed the cross-over phase and 44
patients the extension phase per protocol (Fig 1).
Inclusion criteria included age between 18 and< 99 years and CKD G5 (GFR <15ml/min/
1.73m2) requiring hemodialysis treatment thrice weekly since at least three months. Patients
had to have a permanent vascular access (fistula, graft or a tunneled central venous catheter).
Participation in the trial was impossible, if patients were unable or unwilling to give informed
written consent, or were pregnant or breast feeding, had a clinically manifest infection or a
CRP value of over 50 mg/l in the last two weeks. Moreover, therapy with immunosuppressive
drugs and concurrent participation in another interventional study were exclusion criteria.
Study treatment
The study was registered at ClinicalTrials.gov (NCT02084381). The study was conducted in
accordance with the ethical principles of the Declaration of Helsinki and approved by the Eth-
ics Committees of the Martin-Luther-University Halle-Wittenberg and the Charite´, Berlin.
After informed written consent, the patients were randomized to one of two treatment regi-
mens at a 1:1 ratio (block randomization with site as stratification factor). The random alloca-
tion was generated from a table of random numbers kept at the ‘The Coordination Center for
Clinical Studies (KKS), Halle. The allocation code was transmitted to study physicians by fax.
The trial was not blinded neither to patients nor to physicians, while laboratory staff remained
blinded until data was cleared and the database closed.[11]
Throughout the whole trial all patients were treated with hemodialysis, hemodiafiltration
was not conducted.
During the run-in phase of 12 dialysis sessions all patients were treated with High-flux dia-
lyzers (Revaclear 400, Gambro Dialysatoren GmbH, Hechingen, Germany). Revaclear 400 dia-
lyzers were used when High-flux is declared. Group A continued on this membrane while
group B was switched to a MCO dialyzer prototype (MCO-Ci 4001, Gambro Dialysatoren
GmbH, Table 1).[14]
The dialysis regimen of each patient including blood flow, dialysate flow and treatment
time duration per session was not altered. After 12 treatments (4 weeks) a 4-week wash-out
phase using High-flux dialyzers was performed to minimize carry-over-effects. Afterwards,
patients crossed over to the other dialyzer for 4 weeks. Subsequently, to examine long-term
effects, patients were treated for another 8 weeks with the dialyzer they were assigned to in the
previous phase (Fig 1). The total duration of the study including the initial run-in phase was
therefore 24 weeks. All patients were treated with bicarbonate dialysate of ultrapure quality;
dialyzers were used only once. Blood samples were drawn prior to the dialysis sessions at the
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Fig 1. Patient Flow Chart.
doi:10.1371/journal.pone.0169024.g001
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beginning and at the end of each period. At the beginning of each cross-over period, blood
samples were also drawn before the first dialysis session. There were no changes to the protocol
during the conduct of the study.
Primary and secondary endpoints
Based on results from earlier clinical trials conducted with HCO dialyzers [11] we chose to
examine the pre-dialysis TNF-α and IL-6 mRNA expression level in peripheral blood mono-
nuclear cells (PBMC) before and after each 4-week cross-over period as the primary endpoint.
Secondary endpoints were plasma concentrations of multiple pro- and anti-inflammatory
mediators.
Laboratory analysis
Gene transcription analysis of TNF-α and IL-6. Gene transcription analysis of TNF-α
and IL-6 were conducted as described earlier. [11] Briefly, the blood samples were collected
into Tempus™ Blood RNA Tubes containing RNAse inhibitor (ThermoFisher Scientific) and
immediately frozen at -20˚C. Total RNA was extracted with Tempus™ Spin RNA Isolation Kit
(ThermoFisher Scientific), followed by reverse transcription (500 ng of total RNA) with High
Capacity cDNA Reverse Transcription Kit (Life Technologies). Amplification of all qPCR
products was conducted in MicroAmp1 96-well plates (Life Technologies) by employment of
StepOnePlus™1 Real-Time PCR System (Life technologies) and following TaqMan Assays:
TNF-α (Hs01113624_g1), IL-6 (Hs00985639_m1), ACTB (Beta actin, Hs99999903_m1) and
RPL37A (Ribosomal Protein L37A, Hs99999903_m1, all from Life technologies). Thermal
cycling conditions were performed according to manufacturer’s instructions.
For evaluation purposes, TNF-α and IL-6 expression was normalized with two housekeep-
ing genes (ACTB and RPL37A) and divided by internal calibrator to obtain the fold of differ-
ence value (arbitrary unit for mRNA level) in comparison to the reference (positive control).
For data evaluation, DataAssist Software (Life Technologies) was employed.
Soluble markers. Immune mediators were analyzed from citrate plasma using the com-
mercially available Milliplex human Cytokine assay system (Millipore) to detect 19 proteins
(GM-CSF, GRO, INF-γ, IL-10, IL-12(p40), IL-12(p70), IL-17A, IL-1β, IL-1ra, IL-2, IL-4, IL-6,
IL-8, MCP-1, MIP-1α, MIP-1β, sCD40L, sIL2-Ra, TNFα); FGF23, Insulin and Leptin were
measured using the Milliplex human bone panel. A multiplexed Luminex-based immunoassay
for soluble receptor proteins (ICAM, RAGE, VCAM, MIF, gp130, sTNF-R1, sTNF-R2, Fas,
E-Selectin, sIL6R), Rantes, MIF, and Lipoprotein-associated phospholipase A2 (PLA2) was
developed and validated in-house as described before by Hsu et al.[16]
For quantification of interleukin-6 (IL-6) the Quantikine HS human IL-6 ELISA kit, for com-
plement factor D (CFD) the human CFD ELISA kit, for uPAR the human uPAR ELISA kit (R&D
























236 190 1.8 35 54 Steam
PAES, polyarylethersulfone; PVP, polyvinylpyrrolidone; UF, ultrafiltration.
doi:10.1371/journal.pone.0169024.t001
MCO Dialysis Modulates Inflammation in Dialysis Patients
PLOS ONE | DOI:10.1371/journal.pone.0169024 January 13, 2017 5 / 15
Systems, Minneapolis, USA); for α1-microglobulin (α1M) the 1M ELISA kit (Abcam, Cambridge,
UK); for YKL-40 the MicroVue YKL-40 ELISA kit (Quidel, San Diego, USA) were used according
to manufacturers’ instructions.
Kappa and lambda free light chains (FLC), β-2-microglobulin and myoglobin were quanti-
fied by nephelometry on a Siemens BN Prospec Analyzer (Siemens, Marburg, Germany) with
Freelite FLC detection kits (The Binding Site, Birmingham, UK) or BN Prospec System
reagent kits for β-2-microglobulin or myoglobin (Siemens, Marburg, Germany) as previously
described [17–19].
Serum albumin, CRP, urea, creatinine, electrolytes, hemoglobin and platelets were mea-
sured at the central laboratories of the local university clinics.
Statistics
The design of the study, crossover with extension of second period, required modified defini-
tions of study populations. The two populations used in our analysis were
(Modified) ITT-CRO Population (Intent To Treat crossover phase): Includes all patients
with measurements from at least one period of the crossover part and without clinical events
which make measurement of primary endpoint impossible.
(Modified) ITT-EXT Population (Intent To Treat crossover phase plus extension phase):
Includes all patients which are ITT-CRO and which contribute measurements from at least
one visit of the extension part and which had no clinical events which make measurement of
the primary endpoint impossible during the extension part.
The complete definitions of populations are given in the supplement.
The primary analysis population is the modified ITT-CRO population. Patients with clini-
cal events making the analysis of the primary endpoint impossible were excluded after a blind
data review. The remaining drop outs were included in the analysis if results were available for
at least one treatment period.
Assessment of Populations: Populations were assessed in a blind data review. In this review,
data were blinded for treatment (experimental, control). Blinding for periods (time sequence)
was not possible, as study deviations only appeared in crossover period 2 or during the exten-
sion part of the study. The criteria for assessing a specific subject in an analysis population
were predefined with the option of modification during the casuistic assessment process.
Categorical variables are presented as percentage of patients. Continuous data are expressed
as means and standard deviation or median, interquartile range where appropriate. Quantita-
tive variables were assessed for normal distribution. If necessary, log transformations were
applied. In general, the log transformation provided acceptable fit to normal distribution for
the lab values and vital signs under investigation. Linear models with generalized estimating
equations (GEE) were used for baseline adjusted intra-individual comparisons. The model
contained baseline as continuous covariate for each crossover phase, treatment and time as
binary factors. The exchangeable correlation structure was chosen. The primary analysis
referred to the null hypothesis “treatment parameter = 0”. The sample size estimation was
done for a simple t-test, based on an effect size of 0.5 (as seen in a preceding study[11]) and a
drop out rate of 30%.
Imputation of missing values was not performed.
The level of significance was 0.05 (two-sided) but only the primary endpoint was tested
confirmatory. P-values in secondary analyses serve descriptive purposes. All analyses were
done using SPSS for Windows (release 21) at the Institute for Clinical Epidemiology and
Applied Biometry, University of Tu¨bingen.
MCO Dialysis Modulates Inflammation in Dialysis Patients
PLOS ONE | DOI:10.1371/journal.pone.0169024 January 13, 2017 6 / 15
Results
Table 2 gives the demographic data of the ITT-CRO population which included 48 patients.
There were no significant differences between the patients randomized to MCO first or to
High-flux first. Fig 1 denotes the patients’ flow chart during the trial periods.
Primary endpoint
The primary endpoint, TNF-α mRNA and IL-6 mRNA transcripts, was significantly different
between MCO-Ci and High-flux (Table 3). Both transcripts were downregulated at the end of
the crossover treatment period with High-flux as well as with MCO-Ci. However, MCO-Ci
reduced the expression of TNF-α mRNA as well as IL-6 mRNA to a larger extent as compared
to HF. After retransformation of logarithmically transformed data, measurements after MCO
were reduced to 82% of those after HF (95% CI 74%–91%). Fig 2 illustrates the dialyzer effect
on gene transcripts for each individual patient.
No interaction terms with treatment were significant. Thus, analyses stratified for baseline
or treatment period were not necessary. However, for the primary endpoint, the different
study centers were analyzed separately. Results were comparable to the overall analysis. For
both Halle (p< 0.001) and Berlin (p = 0.010) MCO-Ci revealed significantly lower expression
of TNF-α mRNA as compared to HF. A time effect (crossover period 2> crossover period 1)
was significant only in Berlin (p< 0.001), but not in Halle (p = 0.168). Baseline was signifi-
cantly correlated with outcome in both study centers. In summary, the results in the study cen-
ters were coherent and support the primary analysis indicating superiority of MCO-Ci
compared to High-flux. Further sensitivity and subgroup analyses showed that this difference
is primarily borne by crossover period 1 (even so time treatment interaction was not signifi-
cant) and that there seem to be differences between study centers Halle and Berlin.
Additionally, an analysis combining the second crossover period 2 with the extension
period (12 weeks in parallel group design ignoring crossover period 1) was done. However,
here no significant difference was seen between the two membranes for TNF-α mRNA nor IL-
6 mRNA.
Secondary endpoints
During the trial a broad panel of immune-modulatory plasma proteins were measured. The
plasma levels before and after the 4 weeks cross-over phases are listed in Table 3. Listed are
only those parameters that changed significantly during the MCO-Ci phase. All other parame-
ters did not change significantly. Many of the reported parameters also changed during the
High-flux period; a significant difference between MCO-Ci and High-flux dialyzers was
observed only for sTNF-R1, kappa and lambda free light chains, albumin and urea (decrease
during MCO-Ci) and Lp-PLA2 (increase during MCO-Ci).
Serum albumin was influenced by the MCO-Ci membrane; however, no albumin substitu-
tion was necessary in any of the participating patients. There was a significant decrease in
serum albumin in the MCO-Ci phase (from 37.0±3.6 to 35.3±3.7 g/L, p<0.01) while albumin
remained stable in the High-flux phase (baseline: 36.6±3.2, 4 weeks: 37.5±2.7 g/L).
Extension phase
Primary endpoints and safety-related endpoints were obtained before and after the extension
phase in which patients were dialyzed for additional 8 weeks with the assigned dialyzer. As
shown in Table 4, serum albumin was stable after 8 weeks with High-flux (37.6 to 37.9 g/l),
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and increased non-significantly after 8 weeks with MCO-Ci (35.7 to 36.4 g/l). TNF-α mRNA
and IL-6-mRNA remained stable over the course of this 12-week phase Table 4).
Treatment with the MCO-Ci dialyzer was generally well tolerated. 16 serious adverse events
(SAE) occurred throughout the trial (Table 5). 4 SAE arose while the patients were treated
with High-flux dialyzers and 6 while treated with the MCO-Ci dialyzer. 4 SAE were classified
as severe, of these 3 during High-flux period and 1 during the washout period after cross-over
Table 2. Demography and Clinical Patient Data ITT Population.
MCO first (n = 23) HF first (n = 25) p-value
Demography
Patients Age (years) 58.1±16.6 59.8±16.5 0.72
Male Patients n = 19 (83%) n = 16 (64%) 0.2
Female Patients n = 4 (17%) n = 9 (36%)
Patients at Centre Berlin n = 11 (48%) n = 13 (52%) 0.77
Patients at Centre Halle n = 12 (52%) n = 12 (48%)
Anthropometry
Body Height (cm) 173.6 (±8.6) 171.5 (±7.4) 0.38
Body Weight (kg) 83.3 (±13.7) 79.2 (±15.0) 0.58
BMI (kg/m2) 27.6 (±4.1) 27.1 (±5.4) 0.66
Medical History
Dialysis vintage (months) 77.3 (±78) 54.0 (±50) 0.35 (Mann Whitney)
Venous access*
AV Fistula 21 24 0.42 (Monte Carlo)
Graft 2 1
Tunneled catheter 2 0
Underlying Renal Disease
Diabetic nephropathy 3 (13) 5 (20) 0.093 (Monte Carlo simulation used because of small cell frequencies)
Glomerulonephritis 4 (17) 5 (20)
Interstitial, Analgetics, Reflux 3 (13) 2 (8)
Cysts 1 (4) 5 (20)
Hypertension, Glomerulosclerosis 6 (26) 0 (0)
Others 6 (26) 7 (28)
Unknown 0 (0) 1 (4)
Screening/Baseline
Diastolic blood pressure (mmHg) 78.2 (±12.7) 75.7 (±13.0) 0.51
Systolic blood pressure (mmHg) 140.0 (±22.0) 141.2 (±23.4) 0.84
Blood flow (ml/min) 299 (±38,4) 299 (±30,8) 0,55
Dialysis time/session (min) 267 (±21,2) 263 (±18,992) 0,76
Total UF (ml) 2304 (±932) 1926 (±942) 0.17
Residual urine output
0–499 ml/d 16 (70) 14 (56) 0.38
>500ml/d 7 (30) 11 (44)
Anticoagulation
Heparin-fractionated 5 (22) 3 (12) 0.45
Heparin non-fractionated 18 (78) 22 (88)
Abbreviation: MCO = medium cut-off; HF = high flux, Entries are absolute and percentage frequencies and means ± Standard Deviations* P-values refer to
two-sided t-tests and chi-square tests if not stated explicitly.
*Discrepancy caused by change of access during trial.
doi:10.1371/journal.pone.0169024.t002
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periods. No SAE was classified as related to the study product. In 11 of the 16 SAEs, patients
fully recovered, one death occurred during the High-flux period (Table 5).
Discussion
The present clinical trial examined the middle-term effects of the newly developed MCO-Ci
membranes. Our results show that both TNF-α and IL-6 mRNA are lowered to a greater extent
with MCO-Ci compared to High-flux. This underlines the capacity to reduce the inflammatory
level in chronic dialysis patients with MCO-Ci dialysis.
We chose TNF-α and IL-6 mRNA in blood leukocytes as the primary endpoint for a variety
of reasons. First, in a previous trial using HCO dialyzers we found that gene expression in
peripheral blood is a reliable marker to study inflammation in hemodialysis patients [11]. Sec-
ond, interpretation of the measured concentrations of serum parameters depends on several
Table 3. Primary endpoints (TNF- αmRNA / IL-6 mRNA) and long-term plasma levels before and after 4 weeks treatment with High-flux / MCO.
Shown are only parameters with a significant change after the MCO-period.
High-flux MCO p MCO vs HF
T = 0 T = 4 weeks T = 0 T = 4 weeks
Primary endpoint
TNF-αmRNA 1.19 ± 0.57 1.02 ± 0.49* 0.92 ± 0.34 0.75 ± 0.31** < 0.001
IL-6 mRNA 0.86 ± 0.68 0.83 ± 0.67 0.78 ± 0.80 0.60 ± 0.43** 0.001
Clinical chemistry
Albumin g/l 36.6 ± 3.2 37.5 ± 2.7 37.0 ± 3.6 35.3 ± 3.7** < 0.001
CRP mg/l 13.4 ± 25.5 9.6 ± 15.7 15.3 ± 30.0 9.3 ± 14.5 n.s.
Urea mg/dl 131± 38 129 ± 35 128 ± 34 115 ± 29** 0.012
Beta2M mg/l 27.0 ± 9.1 26.1 ± 8.6 26.9 ± 8.4 25.7 ± 8.1** n.s.
TNF-/TNFR-Family
sTNF-R1 ng/ml 13.3 ± 4.7 12.9 ± 4.7 13.0 ± 4.4 11.0 ± 3.7** 0.01
sTNF-R2 ng/ml
TNF-α pg/ml 23.4 ± 7.3 22.2 ± 6.0 24.1 ± 8.1 20.6 ± 5.8** n.s.
sCD40 pg/ml 2238 ± 1705 2044 ± 1382 2403 ± 1980 1867 ± 1297* n.s.
Main cytokines
IFN-γ pg/ml 16.0 ± 19.7 14.4 ± 17.8 17.5 ± 19.2 11.8 ± 12.7** n.s.
IL-17 pg/ml 7.2 ± 7.9 6.5 ± 6.9 8.9 ± 9.5 5.4 ± 5.6** n.s.
IL-10 pg/ml 59 ± 355 47 ± 280 51 ± 287 65 ± 402** n.s.
IL-12p40 pg/ml 22.8 ± 16.4 25.4 ± 24.0 26.9 ± 23.1 21.3 ± 17.3* n.s.
IL-6 pg/ml 9.8 ± 20.5 5.5 ± 4.5* 9.0 ± 13.2 6.0 ± 5.9** n.s.
Chemotaxis/Adherence
IL-8 pg/ml 11.7 ± 8.5 10.9 ± 7.9 13.0 ± 9.5 10.8 ± 7.8* n.s.
MCP-1 pg/ml 480 ± 219 466 ± 152 492 ± 166 444 ± 151* n.s.
MIP-1b pg/ml 24.8 ± 15.3 22.8 ± 13.6 26.9 ± 15.5 22.1 ± 11.8** n.s.
sVCAM ng/ml 166 ± 31 150 ± 43** 163 ± 41 149 ± 32* n.s.
Other
FLC kappa mg/l 134 ± 65 140 ± 77 137 ± 65 120 ± 54** 0.003
FLC lambda mg/l 91 ± 42 91 ± 44 95 ± 46 79 ± 36** < 0.001
Fetuin A μg/ml 569 ± 124 543 ± 122 560 ± 131 519 ± 112* n.s.
Lp-PLA2 ng/ml 180 ± 90 185 ± 108 156 ± 76 189 ± 101** 0.026
* = p<0.05 vs. T = 0
** = p<0.01 vs. T = 0.
doi:10.1371/journal.pone.0169024.t003
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factors. Binding to other proteins such as soluble receptors, formation of multimers, distribu-
tion and re-shift from tissue and other factors influence serum concentrations of interleukins
and makes their measurement and interpretation difficult. MRNAs of inflammatory parame-
ters such as IL-6 and TNF-α on the other hand are intracellular markers and are thus not elim-
inated during dialysis.
Intracellular inflammatory parameters are hence better suited than plasma levels as markers
of microinflammation.
Besides the significant reduction of the mRNAs the serum concentrations of TNF-α and
IL-6 were also reduced significantly with MCO but the reduction was not significant when
compared to High-Flux. IL-6 and TNF-α are important inflammatory proteins in the process
of inflammation and correlate with cardiovascular events in the dialysis population. [20–22]
Other interleukins that were significantly reduced with MCO-Ci included sTNFR1. In
accordance with the results of the PERCI-I-trial, levels of sTNFR1 were lowered significantly
better with MCO-Ci dialysis compared to High-Flux. sTNFR1 is known as a predictor of car-
diovascular mortality in chronic dialysis patients [23]. It seems possible, that the drop of this
18 kD -molecule was partially caused by improved elimination. However, since we did not
measure sTNFR1 concentrations in dialysate samples other factors such as reduced sTNFR1
production as a result of generally lowered microinflammation may also have played a role.
On a regulatory point of view the TNF-/TNFR superfamily seems to play an important
role in this setting. It fits in the line that sTNFR1 which is believed to have a dual role–(firstly
sTNFR acts as a neutralizing and buffering component for circulating TNF-α secondly the sol-
uble receptor may induce apoptosis via reverse TNF-α-signaling)—is significantly decreased
by MCO-Ci-treatment.
After four weeks of MCO-Ci dialysis Interleukin-10 and Lp-PLA2 increased significantly.
While IL-10 is known as antiinflammatory, the role of Lp-PLA2 in the process of atherosclero-
sis is poorly understood and controversely discussed in the literature [24–26].
Several other molecules were significantly changed after MCO-Ci dialysis, but lacked signif-
icance when compared to high-flux dialysis (see Table 3). Taken together, the MCO-Ci dia-
lyzer appears to influence the inflammatory signature of immune regulatory lymphocytes and
monocytes, as most of the main inflammatory cytokines of both leukocyte subsets are downre-
gulated (Table 3).
Fig 2. Expression of TNF-mRNA and IL-6-mRNA (log scale of arbitrary units) before and after the
cross-over periods using High-flux or MCO dialyzers. Each dot (MCO: solid; Highflux: open) represents a
single patient. Note that the regression line of the MCO phase is lower and does not cross the line of the High-
flux period; the difference between High-flux and MCO is significant, p<0.01.
doi:10.1371/journal.pone.0169024.g002
Table 4. Primary endpoints and plasma levels of Albumin, Free light chains and soluble TNF receptor 1 during the second crossover phase (4
weeks) and the extension phase (8 weeks).
High-Flux MCO P (MCO vs Highflux,
Start phase 2—End
phase 3)
Start Phase 2 End Phase 2 End Phase 3 Start Phase2 End Phase 2 End Phase 3
TNF-alpha mRNA RQ 1.06 (±0.62) 1.06 (±0.67) 1.03 (±0.43) 0.85 (±0.33) 0.80 (±0.25) 0.87 (±0.31) 0,702
IL-6 mRNA RQ 0.91 (±0.82) 1.00 (±0.85) 0.89 (±0.73) 0.52 (±0.26) 0.53 (±0.29) 0.62 (±0.42) 0,414
Kappa FLC mg/L 147.83 (±64.35) 150.39 (±76.33) 144.51 (±71.07) 140.76 (±68.72) 117.03 (±55.53) 113.96 (±54.95) 0,001
Lambda FLC mg/L 90.97 (±33.02) 93.92 (±38.92) 89.61 (±36.39) 96.28 (±56.14) 80.50 (±43.97) 75.98 (±37.89) <0,0001
sTNFr-1 ng/mL 13.09 (±3.7) 12.605 (±4.6) 12.99 (±4.9) 12.76 (±4.68) 10.81 (±4.39) 10.44 (±3.65) 0,006
Albumin g/L 35.98 (±2.99) 37.6 (± 2.3) 37.86 (±3.47) 37.16 (±4.08) 35.7 (±4.5) 36.41 (±3.89) <0,0001
doi:10.1371/journal.pone.0169024.t004
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Besides modulation of inflammation we examined the course of albumin concentrations
with MCO-Ci dialysis. Our results demonstrate that in spite of the steeper cut-off compared to
High Cut-off membranes loss of albumin remains an important issue in patients treated with
MCO dialysis. In accordance with the first clinical trial in which MCO dialyzers came to use
we noted that with the use of MCO-Ci filters the drop in in mean albumin concentration was
less than 2 g/L and thus albumin loss seems to be limited compared to HCO.[11] We did not
conduct systematic measurements of albumin concentrations in the dialysate. But considering
the higher cut-off of the membrane it seems highly likely that lower albumin concentrations
after MCO dialysis is brought about by increased albumin filtration and/or membrane
adherence.
Extending the use of MCO for another 8 weeks did not result in further reductions in
serum albumin but even increased again.
Moreover, the number of clinically overt side effects was similar in both treatment arms
and no AE related to hypalbuminemia was reported. During both the two 4-weeks period and
the 8-weeks extension period SAEs were equally distributed in both treatment arms without
statistical significant differences.
Still, the extent of albumin loss has to be considered as low albumin levels are associated
with negative long-term adverse outcomes due to malnutrition. This is an important aspect
that has to be evaluated in future trials.
Thus, trials with longer lasting treatment periods and clinical endpoints are desirable to
analyze this matter further.
The present study has a number of advantages over previous trials on this matter. It investi-
gated the middle-term effects of dialyzers on cytokine levels and inflammatory parameters.
Most previous studies on HCO and MCO only examined short term effects on plasma levels
or dialyzer clearances.[27]
Limitations
By design, our trial focuses on surrogate parameters. Therefore, no statements can be made
regarding clinical endpoints. Furthermore, we only used both dialyzers in a diffusive mode
and cannot state whether MCO-Ci dialysis is superior to HDF regarding the elimination of
middle-sized molecules.
Also, the study was an open-label study only blinded to staff performing the lab analysis
and the data review, but not to patients and dialysis nurses and doctors. Even though this trial
was monitored carefully, this may possibly have interfered with the interpretation of filter tol-
erance and (S)AEs.
Table 5. Number of patients with serious adverse events while being treated in the study (+ 15 days after end of study). (ITT population, n = 48).









SAE 2 4 6 3 15
Severe SAE 0 3 0 1 4
SAE Related to Study Product 0 0 0 0 0
Study Product permanently
stopped
0 1 0 0 1
Fully Recovered 1 3 5 2 11
Death 0 1 0 0 1
doi:10.1371/journal.pone.0169024.t005
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Moreover, we saw a difference regarding the results during both treatment periods and in
the extension period. While there was a great difference in the primary endpoint with respect
to the dialyzer in the first phase, no significant difference was noted in the second phase and
the extension period. Even though no significant carryover effect was noted in the statistical
analysis, it can be suspected that the MCO treatment caused longer lasting effects than
expected. In the group that started with MCO, possibly the preceding treatment with MCO
may have interfered with the results from the second phase using HF. In future trials a mere
parallel group design thus appears preferable.
Finally, cytokine or albumin removal was not analyzed by collecting complete spent dialy-
sate. We decided against this option because most cytokines in blood are at a very low concen-
tration range of pg/mL that will even be lower in diluted dialysate. Cytokine concentrations in
dialysate samples would therefore be below the detection limit of most assays. Furthermore,
possibly a significant portion may be lost via membrane adherence and thus would also be
missed with analysis of the dialysate.
It therefore, remains somewhat unclear whether the effects on serum concentrations of the
investigated parameters are due to reduced production or enhanced elimination.
In summary, we demonstrated a trial with MCO-Ci membranes with treatment periods
of up to twelve weeks. The use of MCO-Ci reduced the primary endpoint TNF-α and IL-6
mRNA expression in peripheral blood to a significantly greater extent compared to High-
flux dialyzers. 4 weeks use of MCO-Ci resulted in a persistent change in plasma levels of sev-
eral cytokines and other substances with a significant difference to High-flux for sTNFR1,
kappa and lambda free light chains, albumin, urea and Lp-PLA2. While the present trial
focuses on dampening chronic inflammation in dialysis patients, the results also suggest
MCO-Ci dialysis as a treatment option for other disease entities demanding removal of sol-
utes in this molecular size range such as free light chains, myoglobin, and cytokines in sep-
sis. Thus, possible indications that have to be assessed in future trials may include sepsis,
multiple myeloma and rhabdomyolysis.
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